Cargando…
Outcome of COVID-19 Infection in Patients With Multiple Sclerosis Who Received Disease-Modifying Therapies: A Systematic Review and Meta-Analysis
BACKGROUND AND PURPOSE: A systematic review and meta-analysis was performed of the outcome of Coronavirus disease 2019 (COVID-19) infection in patients with multiple sclerosis (MS) who received disease-modifying therapies (DMTs). METHODS: Relevant studies published before November 2022 in the PubMed...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Neurological Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329925/ https://www.ncbi.nlm.nih.gov/pubmed/36929061 http://dx.doi.org/10.3988/jcn.2022.0348 |
_version_ | 1785070120427585536 |
---|---|
author | Liu, Ning Yu, WuHan Sun, Mengjiao Zhang, Wenjing Zhou, Dan Sun, Jing Wang, ManXia |
author_facet | Liu, Ning Yu, WuHan Sun, Mengjiao Zhang, Wenjing Zhou, Dan Sun, Jing Wang, ManXia |
author_sort | Liu, Ning |
collection | PubMed |
description | BACKGROUND AND PURPOSE: A systematic review and meta-analysis was performed of the outcome of Coronavirus disease 2019 (COVID-19) infection in patients with multiple sclerosis (MS) who received disease-modifying therapies (DMTs). METHODS: Relevant studies published before November 2022 in the PubMed, Cochrane Library, Chinese National Knowledge Infrastructure, and Web of Science databases were retrieved using the following search expression: (“multiple sclerosis” OR “MS”) AND (“DMT” OR “disease modifying therapies”) AND (“COVID-19”). Two authors independently screened the articles and extracted the data. Qualitative analyses and a meta-analysis constituted 22 of the 794 retrieved articles. Differences in the hospitalization and mortality rates were used as the main measures of efficacy, and the meta-analysis was performed using RevMan software. RESULTS: 22 clinical trials were selected. The hospitalization rate was lower in the 3,216 patients who received DMTs than in the 774 patients who did not receive any treatment, with a moderate effect size of 0.43 (p<0.00001). The mortality rate was also lower among patients with MS treated using DMTs than in controls (odds ratio [OR]=0.19, 95% confidence interval [CI]=0.13–0.27, p<0.00001). The hospitalization rates for COVID-19 infection in patients with MS treated with anti-CD20 therapy also increased markedly (OR=3.32, 95% CI=2.63–4.20, p<0.00001). However, there was no significant difference between patients with MS who did and did not receive DMTs. CONCLUSIONS: In summary, the application of DMTs was found to be valuable for patients with MS infected with COVID-19. However, more clinical studies are needed to determine the use of anti-CD20 drugs in patients with MS during the COVID-19 pandemic. |
format | Online Article Text |
id | pubmed-10329925 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Korean Neurological Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-103299252023-07-11 Outcome of COVID-19 Infection in Patients With Multiple Sclerosis Who Received Disease-Modifying Therapies: A Systematic Review and Meta-Analysis Liu, Ning Yu, WuHan Sun, Mengjiao Zhang, Wenjing Zhou, Dan Sun, Jing Wang, ManXia J Clin Neurol Original Article BACKGROUND AND PURPOSE: A systematic review and meta-analysis was performed of the outcome of Coronavirus disease 2019 (COVID-19) infection in patients with multiple sclerosis (MS) who received disease-modifying therapies (DMTs). METHODS: Relevant studies published before November 2022 in the PubMed, Cochrane Library, Chinese National Knowledge Infrastructure, and Web of Science databases were retrieved using the following search expression: (“multiple sclerosis” OR “MS”) AND (“DMT” OR “disease modifying therapies”) AND (“COVID-19”). Two authors independently screened the articles and extracted the data. Qualitative analyses and a meta-analysis constituted 22 of the 794 retrieved articles. Differences in the hospitalization and mortality rates were used as the main measures of efficacy, and the meta-analysis was performed using RevMan software. RESULTS: 22 clinical trials were selected. The hospitalization rate was lower in the 3,216 patients who received DMTs than in the 774 patients who did not receive any treatment, with a moderate effect size of 0.43 (p<0.00001). The mortality rate was also lower among patients with MS treated using DMTs than in controls (odds ratio [OR]=0.19, 95% confidence interval [CI]=0.13–0.27, p<0.00001). The hospitalization rates for COVID-19 infection in patients with MS treated with anti-CD20 therapy also increased markedly (OR=3.32, 95% CI=2.63–4.20, p<0.00001). However, there was no significant difference between patients with MS who did and did not receive DMTs. CONCLUSIONS: In summary, the application of DMTs was found to be valuable for patients with MS infected with COVID-19. However, more clinical studies are needed to determine the use of anti-CD20 drugs in patients with MS during the COVID-19 pandemic. Korean Neurological Association 2023-07 2023-03-13 /pmc/articles/PMC10329925/ /pubmed/36929061 http://dx.doi.org/10.3988/jcn.2022.0348 Text en Copyright © 2023 Korean Neurological Association https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Liu, Ning Yu, WuHan Sun, Mengjiao Zhang, Wenjing Zhou, Dan Sun, Jing Wang, ManXia Outcome of COVID-19 Infection in Patients With Multiple Sclerosis Who Received Disease-Modifying Therapies: A Systematic Review and Meta-Analysis |
title | Outcome of COVID-19 Infection in Patients With Multiple Sclerosis Who Received Disease-Modifying Therapies: A Systematic Review and Meta-Analysis |
title_full | Outcome of COVID-19 Infection in Patients With Multiple Sclerosis Who Received Disease-Modifying Therapies: A Systematic Review and Meta-Analysis |
title_fullStr | Outcome of COVID-19 Infection in Patients With Multiple Sclerosis Who Received Disease-Modifying Therapies: A Systematic Review and Meta-Analysis |
title_full_unstemmed | Outcome of COVID-19 Infection in Patients With Multiple Sclerosis Who Received Disease-Modifying Therapies: A Systematic Review and Meta-Analysis |
title_short | Outcome of COVID-19 Infection in Patients With Multiple Sclerosis Who Received Disease-Modifying Therapies: A Systematic Review and Meta-Analysis |
title_sort | outcome of covid-19 infection in patients with multiple sclerosis who received disease-modifying therapies: a systematic review and meta-analysis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329925/ https://www.ncbi.nlm.nih.gov/pubmed/36929061 http://dx.doi.org/10.3988/jcn.2022.0348 |
work_keys_str_mv | AT liuning outcomeofcovid19infectioninpatientswithmultiplesclerosiswhoreceiveddiseasemodifyingtherapiesasystematicreviewandmetaanalysis AT yuwuhan outcomeofcovid19infectioninpatientswithmultiplesclerosiswhoreceiveddiseasemodifyingtherapiesasystematicreviewandmetaanalysis AT sunmengjiao outcomeofcovid19infectioninpatientswithmultiplesclerosiswhoreceiveddiseasemodifyingtherapiesasystematicreviewandmetaanalysis AT zhangwenjing outcomeofcovid19infectioninpatientswithmultiplesclerosiswhoreceiveddiseasemodifyingtherapiesasystematicreviewandmetaanalysis AT zhoudan outcomeofcovid19infectioninpatientswithmultiplesclerosiswhoreceiveddiseasemodifyingtherapiesasystematicreviewandmetaanalysis AT sunjing outcomeofcovid19infectioninpatientswithmultiplesclerosiswhoreceiveddiseasemodifyingtherapiesasystematicreviewandmetaanalysis AT wangmanxia outcomeofcovid19infectioninpatientswithmultiplesclerosiswhoreceiveddiseasemodifyingtherapiesasystematicreviewandmetaanalysis |